Ignyta, Inc. (OTCQB:RXDX),an oncology precision medicine
biotechnology company, announced today that on February 11, 2014, the
Securities and Exchange Commission declared effective the company's
registration statement on Form S-1 relating to resale of up to 9,010,238
shares of Ignyta's common stock, par value $0.00001 per share, by
certain selling stockholders. The company registered these shares to
satisfy commitments it made in connection with the raising of
approximately $54 million in equity financing to certain institutional
investors and high net worth individuals.

"We are pleased that the SEC (News - Alert) has declared our Form S-1 effective," said
Jonathan Lim, M.D., Chairman and CEO of Ignyta. "This will enable
holders of approximately 67% of our outstanding common stock to offer
and sell their shares from time to time. As a result, we expect that a
more liquid trading market in our shares could develop over the coming
months."

The resale registration statement, while effective, allows selling
stockholders to publicly resell their shares of Ignyta common stock,
subject to the satisfaction by selling stockholders of the prospectus
delivery requirements of the Securities Act of 1933, as amended, in
connection with any such resale. The company will not receive any
proceeds from any sales by selling stockholders, and the company is not
aware of any plans by selling stockholders to effect such resales.

The offering of these securities may only be made by means of a
prospectus. A registration statement relating to these securities has
been declared effective by the Securities and Exchange Commission. The
registration statement may be accessed through the SEC's website at www.sec.gov.
A copy of the prospectus related to the offering may be obtained from
Ignyta, Inc., 11095 Flintkote Ave., Suite D, San Diego, CA (News - Alert) 92121, or by
calling (858) 255-5959.

This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any of the company's securities, nor
shall there be any sale of these securities in any state in which offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state.

About Ignyta, Inc.

Ignyta, Inc., located in San Diego, California, is a biotechnology
company developing precision medicine with integrated Rx/Dx solutions
for cancer patients. Our goal is to discover and develop revolutionary
new drugs that target activated genes in cancer cells for the customized
treatment of cancer patients. Our present focus is on the development of
RXDX-101 and RXDX-102, our proprietary oral tyrosine kinase inhibitors
that target solid tumor indications, and advancing our novel Spark
discovery programs that leverage our proprietary cancer genomic and
epigenomic knowledge bases. For more information, please visit: www.ignyta.com.

Forward-Looking Statements

This press release contains forward-looking statements as that term is
defined in Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934. Statements in this press release
that are not purely historical are forward-looking statements. Such
forward-looking statements include, among other things, references to
the potential for a liquid trading market for our common stock to
develop; our novel technologies and methods; our progress in developing
new oncology therapies; our business and product development plans; and
market information. Actual results could differ from those projected in
any forward-looking statements due to numerous factors. Such factors
include, among others, our ability to raise the additional funding we
will need to continue to pursue our business and product development
plans; the inherent uncertainties associated with developing new
products or technologies and operating as a development stage company;
our ability to develop, complete clinical trials for, obtain approvals
for and commercialize any of our product candidates; competition in the
industry in which we operate and market conditions. These
forward-looking statements are made as of the date of this press
release, and we assume no obligation to update the forward-looking
statements, or to update the reasons why actual results could differ
from those projected in the forward-looking statements. Investors should
consult all of the information set forth herein and should also refer to
the risk factor disclosure set forth in the reports and other documents
we file with the SEC available at www.sec.gov,
including without limitation our Current Report on Form 8-K dated
October 31, 2013 and amended November 14, 2013 and December 9, 2013.